首页/数据集/Cellular androgen content influences enzalutamide agonism of F877L mutant androgen receptor

Cellular androgen content influences enzalutamide agonism of F877L mutant androgen receptor

ChEBI2016-06-10 更新2026-07-12 收录

耐药性前列腺癌

受体突变

数据链接：

https://www.ebi.ac.uk/biostudies/ArrayExpress/studies/E-GEOD-69896 数据链接链接失效反馈

官方服务：

资源简介：

Cellular androgen content influences enzalutamide agonism of F877L mutant androgen receptor

应用场景：

创建时间：

2016-06-10

相关数据集

pdb

蛋白质结构

受体突变

PDB file WT.pdb contains the last frame from 10 ns molecular dynamics simulation alpha7-AChBP chimera (PDB 3SQ6). Only two adjacent subunits were subjected to simulations. PDB files with names E185V,

DataONE2017-08-11 更新110

10-L2146-Triketide-18p

分子对接

受体突变

triketide docked in L2146A mutant ER model

Figshare2020-01-24 更新80

Drug-induced epigenomic plasticity reprograms circadian rhythm regulation to drive prostate cancer towards androgen-independence [Cell line ChIP-Seq]

耐药性前列腺癌

昼夜节律表观遗传调控

In prostate cancer, androgen receptor (AR)-targeting agents are very effective in various stages of the disease. However, therapy resistance inevitably occurs and little is known about how tumor cells

NIAID Data Ecosystem70

High-throughput profiling of mRNA from parental and Enzalutamide resistant C4-2b prostate cancer cell lines

耐药性前列腺癌

RNA表达谱分析

We established an enzalutamide-resistant C4-2b prostate cell line that has an active androgen receptor by maintaining the C4-2b cell line in serially increasing concentrations of enzalutamide. Among t

NIAID Data Ecosystem90

GREB1 amplifies androgen receptor output in prostate cancer and contributes to antiandrogen resistance. GREB1 amplifies androgen receptor output in prostate cancer and contributes to antiandrogen resistance

耐药性前列腺癌

雄激素受体信号

Genomic amplification of the androgen receptor (AR) is an established mechanism of antiandrogen resistance in prostate cancer. Here we show that the magnitude of AR signaling output, independent of AR

NIAID Data Ecosystem70